Rob G J A Zuiker (Rgja Zuiker, Rob Zuiker)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Topics

Major Depressive Disorder

Transcranial Magnetic Stimulation

Placebo Controlled

Top Venues

British journal of clinical pharmacology

Translational psychiatry

Clinical and translational science

Journal of psychopharmacology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Francis M Dijkstra, Rob G J A Zuiker, Jules A A C Heuberger, Kawita M S Kanhai, Marieke De Kam, Thierry Duvauchelle, Jeanne-Marie Lecomte, Olivier Labeeuw, Laurent Landais, Xavier Ligneau, Philippe Robert, Marc Capet, Jean-Charles Schwartz, Joop M A van Gerven
Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: central nervous system depression and pseudo-hallucinations. British journal of clinical pharmacology (2023)
Sander Brooks, Rob G J A Zuiker, C Bleys, D Ziagkos, J A Moyer, L van Nueten, P Bonaventure, W C Drevets, Jma van Gerven, G Salvadore, G E Jacobs
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers. Journal of psychopharmacology (Oxford, England) (2023)
Boudewijn van den Berg, Hemme J Hijma, Ingrid Koopmans, Robert-Jan Doll, Rob G J A Zuiker, Geert Jan Groeneveld, Frans C T van der Helm
Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation. Experimental brain research 240 (2) (2022)
Hemme J Hijma, Ingrid Koopmans, Erica Klaassen, Robert Jan Doll, Rob G J A Zuiker, Geert Jan Groeneveld
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects. British journal of clinical pharmacology (2022)
Francis M Dijkstra, Patricio O'Donnell, Erica Klaassen, Derek L Buhl, Mahnaz Asgharnejad, Laura Rosen, Rob G J A Zuiker, Joop van Gerven, Gabriël Jacobs
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Translational psychiatry 12 (1) (2022)
Francis M Dijkstra, Rob G J A Zuiker, Pieter S Siebenga, Richard A Leigh-Pemberton, Lei Sun, Joan D Manthis, Marieke L de Kam, Richard Lin, Lisa L von Moltke, David Rezendes, Joop M A van Gerven
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers. British journal of clinical pharmacology 88 (6) (2022)
Patricio O'Donnell, Francis M Dijkstra, Ugur Damar, Lei Quanhong, Annika A de Goede, Lin Xu, Andres Pascual-Leone, Derek L Buhl, Rob G J A Zuiker, Titia Q Ruijs, Jules A A C Heuberger, Paul MacMullin, Martin Lubell, Mahnaz Asgharnejad, Venkatesha Murthy, Alexander Rotenberg, Gabriel E Jacobs, Laura Rosen
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. Translational psychiatry 11 (1) (2021)
Robert Rissmann, Rob G J A Zuiker
Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al. British journal of clinical pharmacology 87 (7) (2021)
Matthijs D Kruizinga, Rob G J A Zuiker, Kirsten R Bergmann, Annelies C Egas, Adam A Cohen, Gijs W E Santen, Michiel Joost van Esdonk
Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations. British journal of clinical pharmacology (2021)
Benjamin Berger, Sander Brooks, Rob G J A Zuiker, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS drugs 34 (12) (2020)
Matthijs D Kruizinga, Willem A J Birkhoff, Michiel Joost van Esdonk, Naomi B Klarenbeek, Tomasz Cholewinski, Tessa Nelemans, Melloney J Dröge, Adam A Cohen, Rob G J A Zuiker
Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. British journal of clinical pharmacology 86 (1) (2020)
Kasper Recourt, Jasper van der Aart, Gabriel Jacobs, Marieke de Kam, Wayne Drevets, Luc van Nueten, Kawita Kanhai, Pieter Siebenga, Rob G J A Zuiker, Paulien Ravenstijn, Maarten Timmers, Joop van Gerven, Peter De Boer
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. Journal of psychopharmacology (Oxford, England) 34 (9) (2020)
Kasper Recourt, Peter de Boer, Rob G J A Zuiker, Remy Luthringer, Justine Kent, Peter van der Ark, Ilse Van Hove, Joop van Gerven, Gabriel Jacobs, Luc van Nueten, Wayne Drevets
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Translational psychiatry 9 (1) (2019)
Kasper Recourt, Peter de Boer, Rob G J A Zuiker, Remy Luthringer, Justine Kent, Peter van der Ark, Ilse Van Hove, Joop van Gerven, Gabriel Jacobs, Luc van Nueten, Wayne Drevets
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Translational psychiatry 9 (1) (2019)
Clemens Muehlan, Margaux Boehler, Sander Brooks, Rob G J A Zuiker, Joop van Gerven, Jasper Dingemanse
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. Journal of psychopharmacology (Oxford, England) 34 (3) (2019)